We report on a case of an officer cadet who was inadvertently allowed to commence training with a history suggestive of hypersensitivity to tetanus immunisation and who, eventually, successfully underwent a graduated immunisation regimen. This case combines a search for good evidence with the extraordinary complexities of military medical management and the law. It is a lesson in all three.
Introduction
The Armed Forces immunisation policy requires all recruits to have completed a full course of tetanus immunisation in accordance with the NHS regimen of five injections (1) . This is a key occupational health requirement. Soldiers undergo regular arduous training over varied terrain that includes farmland and there is a significant risk of open wounds, combined with exposure to infection with Clostridium tetani.
As protection against tetanus relies on preexisting antibody levels, rather than an evoked memory response, it is necessary to maintain high resting antibody levels through a comprehensive vaccination programme. For recruits this involves immunisation at the time of the initial medical selection; refusal to immunise, or a history of hypersensitivity that prevents immunisation, is a bar to entry. The available literature suggests that, although a local reaction to tetanus is common, anaphylactic symptoms are extremely rare. Unfortunately, as with many other reactions, recruits tend to report 'allergies' to medication without any clear documented evidence of such.
Case Report
An officer cadet was inadvertently passed fit for entry into the Army at his Pre-Service medical examination, despite a history of a severe reaction to tetanus immunisation as a child. He had completed the initial three courses as an infant, and had a fourth preschool dose with no recorded adverse reaction. While on holiday aged 10 he injured himself and was given a booster dose to which he developed a 'severe local reaction'. He was not given the final school-leavers' dose.
Having uncovered the discrepancy at a routine review during initial officer training, the Medical Officer sent serum to check his immune status; the titration result (49 units/ml against a reference value of 640 units/ml, Birmingham Reference Lab) suggested that he had no protective immunity and so would require further immunisation to continue military training. He was referred, while still in training, to the local immunologist who conducted intradermal skin testing which produced an immediate wheal reaction. The immunologist stated that this was a general indication of an increased risk of anaphylactic reaction and recommended that immunisation should be conducted in a 'safe environment', i.e. a hospital which could deal with any anaphylactic reaction.
The officer cadet was therefore referred to a Service physician for immunisation; this physician refused to take the risk on the evidence presented, which complicated the matter as by then the officer cadet was two weeks from completing his commissioning course. Further advice, sought from the Army's Civilian Consultant Adviser in Occupational Medicine, was that a refusal by a consultant physician altered the legal situation and would require clear evidence to support a decision to immunise. On the other hand, there was considerable pressure from a variety of sources to allow the officer cadet to 'pass out' from his training and continue to serve.
A full literature search was conducted and the manufacturer (Medeva Pharma) was consulted, as was the Medical Defence Union. There was significant evidence that true anaphylaxis to tetanus is very rare (2) . Reported reactions include an immediate anaphylactoid reaction (3); a less frequent Arthus reaction and brachial neuritis are also reported (4). Department of Health (DoH) advice (iv) states that 'an adverse reaction to tetanus toxoid does not preclude future immunisation with this same material. If this is to be done in patients with a history of an adverse reaction to a previous dose, then it is best performed in a setting where there are facilities to deal with any acute allergic reactions.'
The only significant study (5) of individuals with reactions assessed 740 individuals with histories of reactions to tetanus. Seven hundred and thirty had negative skin prick tests and of the ten positive individuals, four had immediate reactivity. Two of these four tolerated a full immunising dose without adverse effects; the other two refused. Ninety-five patients had histories suggestive of prior anaphylactoid reaction and all tolerated full immunising doses. The advice from both DoH and US Department of Health and Human Services (DHHS) is that the only absolute contraindication to an immunising dose is a previous history of anaphylactic reaction and positive skin response. Furthermore, although there is a potential risk of a severe reaction from subsequent immunisation, this is so rare that a balance should be struck with the potential benefits. Somewhat frustratingly, the manufacturers advised that skin prick testing is now inappropriate because intradermal administration of the vaccine may give rise to a persistent nodule. However it was the skin prick testing that pointed to a possible anaphylactic risk, and started this lengthy process off.
Another case history was found describing an individual in the police, a high-risk occupation, with a previous history of immediate hypersensitivity reactions to tetanus toxoid; the history included loss of consciousness, difficulty in breathing and swelling of the face, arms and legs. Recent testing showed a lack of tetanus antibodies. In view of her desire to continue with her work in the police force, she elected to be immunised in a controlled environment. A graded dosing regimen was used to desensitise and immunise with minimal reaction and a good level of immunity was achieved (6).
Having found sufficient evidence to support a decision to immunise, another Army consultant physician was found who agreed to immunise. There followed the classic Service medical tale: the unit would not allow the newly commissioned officer to go to his appointment and he failed to attend. The physician then retired, the occupational physician was posted and the patient was then also posted. Eventually a new appointment was made with a new consultant and immunisation was undertaken nine months after commissioning.
In view of the history, it was decided to try the graded dose regimen reported by Uriel et al (6) . Serum was taken for baseline levels of antibody and then a desensitisation process was undertaken as shown below: a) Patient admitted, IV line established and bloods taken for FBC, U&E, CRP, glucose, LFT, serum for tetanus antibodies. b) Consent confirmed, resuscitation equipment prepared. c) Immunisation commenced, with injections every 30 minutes over a four-hour period, using the regimen and making the observations, shown in Table 1 . d) Patient was kept in the hospital medical unit for 2 hours, before being transferred to a military primary care bed facility for overnight observation.
The first surprise was the result of the baseline antibody levels which at 1.9730 iu/ml represented a significant antibody level, contrary to the original test. However as the original test followed a different analysis protocol, assaying the patient's sample against a reference population value, it is not possible to make direct comparisons with the ELISA protocol used subsequently. The final level was 4.2470 iu/ml, a good protective level of immunisation.
Conclusion
Our conclusion from this tale is that individuals with a history of reaction to tetanus should be immunised before recruit entry; attempting to do so after entry can result in a considerable delay, and associated risk. The literature clearly demonstrates that genuine anaphylactic reaction to tetanus is very rare and even these individuals have been successfully immunised. Immunisation following a graded regimen is a safe and appropriate procedure for hypersensitive individuals at risk of tetanus infection. Where there has been a documented anaphylactic reaction, tetanus antibody levels should be taken and where there are protective levels immunisation should be deferred. Retesting at five-yearly intervals would be prudent.
